Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of tisagenlecleucel in adult refractory or relapsed follicular lymphoma
2017-004385-94Phase 2Active
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in follicular lymphoma (FL), sponsored by Novartis. Primary endpoint: Complete response rate by IRC. Started Jun 2018; status: active.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2017-004385-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004385-94.